Multiple Myeloma

The Patient Perspective: New Multiple Myeloma Drugs

Gary Peterson talks about what the addition of new myeloma medicines means to patients.
Video Library – February 5, 2016
Gary Petersen

There are a number of new options that have come about in the last three weeks as a matter of fact, one of which is daratumumab, and another is elotuzumab. Both of those are something brand new as far as it's a whole new area of treatment that hasn't been developed before.

The other one in the same category is elotuzumab, and then of course there's the oral proteasome inhibitor which is Ninlaro. I think all of these are exciting new drugs. All the doctors that I've talked to, or have seen, are just remarkably overjoyed, like kids in a candy store, with all these new options that they're going to have.

From a patient's perspective, each time there's a new drug, progressions-free survival, and overall survival improve. It's happened with Revlimid, and Velcade. It's happened with Kyprolis, and Pomalidomide, and it's going to happen with these other drugs as well.

From a patient's perspective, there's nothing better than a longer life for a myeloma patient.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: September 30, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.